National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
复制标题
DOI：
10.1016/j.bbmt.2014.12.001
复制
发表时间：
2015-03
期刊：
影响因子：
--
通讯作者：
Flowers ME
中科院分区：
文献类型：
--
作者：
Jagasia MH;Greinix HT;Arora M;Williams KM;Wolff D;Cowen EW;Palmer J;Weisdorf D;Treister NS;Cheng GS;Kerr H;Stratton P;Duarte RF;McDonald GB;Inamoto Y;Vigorito A;Arai S;Datiles MB;Jacobsohn D;Heller T;Kitko CL;Mitchell SA;Martin PJ;Shulman H;Wu RS;Cutler CS;Vogelsang GB;Lee SJ;Pavletic SZ;Flowers ME
2005年美国国立卫生研究院（NIH）共识会议提出了诊断和评分慢性GVHD严重程度的新标准。2014年NIH共识维持了先前共识的框架，并在新证据的基础上进一步完善。为了解决有争议或混淆的领域，例如重叠的慢性GVHD亚类别以及活动性疾病和过去组织损伤之间的区别，已经进行了修订。口腔、眼睛、生殖器和肺部受累的诊断标准已经修订。慢性GVHD的分类应以指示预后、指导治疗和确定临床试验资格的方式进行定义。已经进行了修订，将重点放在器官特异性异常的原因上。慢性GVHD的器官特异性异常的归因已经得到解决。这种范式转变提供了更大的特异性，更准确地衡量GVHD导致的全球疾病负担，并将促进生物标志物关联研究。
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic GVHD. The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity, more accurately measures the global burden of disease attributed to GVHD, and will facilitate biomarker association studies.
登录
查看更多内容
影响因子：
20.3
作者：
Inamoto, Yoshihiro;Storer, Barry E.;Martin, Paul J.
通讯作者：
Martin, Paul J.
影响因子：
11.4
作者：
Cho, B-S;Min, C-K;Kim, C-C
通讯作者：
Kim, C-C
影响因子：
4.8
作者：
Jagasia, M. H.;Abonour, R.;Waller, E. K.
通讯作者：
Waller, E. K.
影响因子：
6.2
作者：
Hirsch, Pierre;Leclerc, Mathieu;Vexiau-Robert, Dominique
通讯作者：
Vexiau-Robert, Dominique
影响因子：
13.7
作者：
Inamoto Y;Chai X;Kurland BF;Cutler C;Flowers ME;Palmer JM;Carpenter PA;Heffernan MJ;Jacobsohn D;Jagasia MH;Pidala J;Khera N;Vogelsang GB;Weisdorf D;Martin PJ;Pavletic SZ;Lee SJ;Chronic GVHD Consortium
通讯作者：
Chronic GVHD Consortium